Navco Pharmaceuticals (TSXV:NAV) ROCE % : 0.00% (As of Mar. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Navco Pharmaceuticals ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Navco Pharmaceuticals's annualized ROCE % for the quarter that ended in Mar. 2023 was 0.00%.

Navco Pharmaceuticals ROCE % Historical Data

The historical data trend for Navco Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Navco Pharmaceuticals ROCE % Chart

Navco Pharmaceuticals Annual Data

Trend

Jun18

Jun19

Jun20

Jun21

ROCE %

-119.35

-27.49

-62.02

Navco Pharmaceuticals Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
ROCE %	Get a 7-Day Free Trial														-65.45	-725.93	-640.00	-	-

Navco Pharmaceuticals ROCE % Calculation

Navco Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Jun. 2021 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Jun. 2021 )		(A: Jun. 2020 )		(A: Jun. 2021 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Jun. 2021 )		(A: Jun. 2020 )		(A: Jun. 2021 )
	=	-0.08	/	( ( (0.181 - 0.02)	+	(0.116 - 0.019) )	/ 2 )
	=	-0.08	/	( (0.161	+	0.097)	/ 2 )
	=	-0.08	/	0.129
	=	-62.02 %

Navco Pharmaceuticals's ROCE % of for the quarter that ended in Mar. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2023 )		(Q: Dec. 2022 )		(Q: Mar. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2023 )		(Q: Dec. 2022 )		(Q: Mar. 2023 )
	=	0.028	/	( ( (0.094 - 0.098)	+	(0.095 - 0.091) )	/ 2 )
	=	0.028	/	( ( -0.004	+	0.004 )	/ 2 )
	=	0.028	/	0
	=	0 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2023) EBIT data.

Navco Pharmaceuticals (TSXV:NAV) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Navco Pharmaceuticals ROCE % Related Terms

Thank you for viewing the detailed overview of Navco Pharmaceuticals's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Navco Pharmaceuticals (TSXV:NAV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Navco Pharmaceuticals Inc (TSXV:NAV) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1055 West Georgia Street, Suite 1500, Vancouver, BC, CAN, V6E 4N7

Website

Navco Pharmaceuticals Inc uses of nanotechnology to develop and commercialize novel products to protect against viruses, bacteria, and infectious diseases. The company's pipeline of applications is tailored to defend against pathogens utilizing new methods of action to capitalize on unmet product needs using natural & known compounds, nanoparticles, and no chemicals with a high degree of efficacy. Its target markets include human health & personal skin care, household & institutional products, and veterinary health.